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Abstract
Introduction Preoperative chemotherapy is often used in
patients with locally advanced breast cancer. However,
commonly used clinical and pathological parameters are poor
predictors of response to this type of therapy. Recent studies
have suggested that altered regulation of the cell cycle in cancer
may be involved in resistance to chemotherapy. Over-expression
of the ubiquitin ligase Skp2 results in loss of the cell cycle
inhibitor p27Kip1 and is associated with poor prognosis in early
breast cancer. The purpose of the present study was to examine
the role of these proteins as predictors of clinical outcome and
response to chemotherapy in locally advanced breast cancer.
Methods The expression levels of Skp2 and p27Kip1  were
determined by immunohistochemistry both before and after
preoperative chemotherapy in 40 patients with locally advanced
breast cancer. All patients were treated with
cyclophosphamide/doxorubicin (adriamycin)/5-fluorouracil
(CAF) and some patients received additional treatment with
docetaxel. Expression data were compared with patients'
clinical and pathological features, clinical outcome, and
response to chemotherapy.
Results Skp2 expression before preoperative chemotherapy
was inversely related to p27Kip1  levels, tumor grade, and
expression of estrogen and progesterone receptors. Both Skp2
and p27Kip1 were found to be accurate prognostic markers for
disease-free and overall survival. High preoperative expression
of Skp2 was associated with resistance to CAF therapy in 94%
of patients (P < 0.0001) but not with resistance to docetaxel.
Conclusion Skp2 expression may be a useful marker for
predicting response to doxorubicin-based preoperative
chemotherapy and clinical outcome in patients with locally
advanced breast cancer.
Introduction
Preoperative chemotherapy is widely used in the management
of primary breast cancer, and particularly in patients who
present with locally advanced disease [1-3]. Studies have
clearly shown that initiating treatment with chemotherapy can
lead to tumor regression in a substantial number of patients,
thereby improving local control and allowing breast-conserv-
ing surgery in many patients without compromising clinical
outcomes [3]. In addition, this practice permits direct assess-
ment of tumor responsiveness to a given drug regimen and
may allow one to determine the need to add or switch to a dif-
ferent regimen. However, not all tumors respond equally to a
given chemotherapy combination. Some tumors may be
responsive only to specific drugs, which may not be in the ini-
tial preoperative protocol used, whereas other tumors may not
respond to a large variety of chemotherapies. This may lead to
unnecessary exposure to drug side effects and loss of time to
treatment, and may enable tumor progression. Unfortunately,
CAF = cyclophosphamide/doxorubicin (adriamycin)/5-fluorouracil; Cdk = cyclin-dependent kinase; ER = estrogen receptor; KIP = kinase inhibitor 
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commonly used clinical and pathological factors are poor pre-
dictors of response to chemotherapy. Therefore, identification
of biological markers that can select those patients who are
most likely to respond to specific preoperative chemotherapy
is of the utmost importance.
The mechanisms responsible for resistance of cancer cells to
chemotherapy, whether inherent or acquired, are poorly under-
stood. Because cell cycle regulation is a key mechanism by
which most chemotherapy agents exert their cytotoxic effect,
alterations that may occur in cell cycle regulation in cancer
may contribute to lack of response to some agents [4]. Under
normal circumstances, progression of the cell cycle is tightly
controlled by timely activation of cyclin-dependent kinases
(Cdks) [5-7]. The progression of each phase of the cell cycle
is promoted by phosphorylation of a variety of proteins by dif-
ferent members of the Cdk family, which in turn are dependent
on the presence of a specific cyclin. In addition, these kinases
are also negatively regulated by specific Cdk inhibitors at dif-
ferent phases in the cell cycle [7].
Recent studies have provided evidence that several Cdk inhib-
itors are targets for genetic changes or are disrupted by other
oncogenic events in human cancers [8,9]. It was also sug-
gested that some of these changes may have important
impacts on the sensitivity of cancer cells to chemotherapy
[10,11]. For example, p21WAF1 (where the definition of WAF1
is 'wild-type p53 activated fragment 1') is a Cdk inhibitor that
blocks the cell cycle at the G1/S transition by inhibiting the
activity of Cdk2 and Cdk4/6 [7]. In response to DNA-damag-
ing agents, wild-type 53 induces the expression of p21WAF1,
leading to cell cycle arrest. Changes in the expression of
p21WAF1 were linked to drug sensitivity in various cancer cell
lines. Cultured breast cancer cells deficient in p21WAF1 exhib-
ited increased response to DNA-damaging agents, whereas
over-expression of p21WAF1 in glioblastoma cells was associ-
ated with increased resistance to nitrosourea and cisplatin
[10,12]. However, studies examining the significance of
p21WAF1 as a prognostic marker or as a predictor of chemore-
sistance in human patients yielded inconsistent findings; low
levels of p21WAF1 were independent prognostic markers for
disease-free survival in some studies but not in others [13-15].
p21WAF1 alone was not found to be associated with resistance
to doxorubicin/mitomycin/5-fluorouracil or doxotaxel in
patients with locally advanced breast cancer, but when com-
bined with low murine double minute gene 2 (MDM2) protein
levels it predicted good response to doxotaxel but not to mito-
mycin/5-fluorouracil [15].
Another Cdk inhibitor that plays a central role in cell cycle reg-
ulation and is thought to affect resistance to anti-cancer drugs
is p27Kip1. p27Kip1 is a member of the CIP/KIP (kinase inhibitor
protein) family that negatively regulates protein kinases Cdk2/
cylin E and Cdk2/cyclin A, which drive cells into the S-phase
of the cell division cycle [7]. In contrast to p21WAF1, its role as
a tumor suppressor and as a prognostic marker in human can-
cers is well established. Loss of p27Kip1 contributes to uncon-
trolled tumor proliferation and is associated with high
aggressiveness and poor prognosis in a large variety of can-
cers, including breast cancer [8,16,17]. It is now apparent that
the loss of p27Kip1 in human cancers results from increased
protein degradation rather than from genetic mutations or
decreased gene expression [18]. This increased degradation
is mediated by the ubiquitin system, resulting in rapid proteas-
ome-mediated degradation of p27Kip1 [19]. The specificity of
the ubiquitin system in targeting proteins for degradation is
defined mainly by its ubiquitin ligase complexes [20]. The
machinery that is involved in targeting p27Kip1 for degradation
is an SCF-type ubiquitin ligase complex that contains S-phase
kinase protein 2 (Skp2) as the specific substrate-recognizing
subunit [21,22].
The role of Skp2 as the main rate-limiting regulator p27Kip1
degradation has been clearly demonstrated in both intact cells
and in cell-free systems, as well as in many human cancers
[21-25]. Skp2 was found to be an oncogene and an independ-
ent prognostic marker for disease-free and overall survival in
breast cancer [26-28]. Moreover, recent studies have showed
that Skp2 also regulates other cell cycle regulators that may
contribute to cancer progression, including c-Myc, cyclin E,
p57Kip2, p21WAP1, and E2F1 [29-32]. However, the effect of
Skp2 on some of the latter proteins is complex. For example, it
has been reported that Skp2 not only targets c-Myc for degra-
dation, but also enhances its transcriptional activity. Thus, it
may be expected that over-expression of Skp2 would
decrease levels of c-Myc, whereas the growth-promoting
action of c-Myc would actually increase [33].
Because alterations in the expression of p27Kip1 profoundly
affect cell cycle regulation in cancer, its role as a potential
marker for chemoresistance has been examined in different
cultured cancer cells. Poor response to cyclophosphamide
was observed in cultured breast cancer cells expressing high
levels of p27Kip1, but sensitivity was restored after downregu-
lation of p27Kip1 [10]. In contrast, low levels of p27Kip1 were
found to be involved in docetaxel resistance [34]. Other stud-
ies suggest that p27Kip1 expression may have anti-apoptotic
effect and prevent drug-induced apoptosis by DNA-damaging
agents, such as cisplatin, leading to drug resistance [35].
Skp2 over-expression is the main factor involved in deregula-
tion of p27Kip1, and Skp2 is also a regulator of other cell cycle
proteins that are involved in tumor progression; therefore, it
may also have important influence on drug resistance. Never-
theless, the role of Skp2 as a predictor to drug resistance
remains unknown.
Doxorubicin (adriamycin) based chemotherapy is highly effec-
tive in the treatment of breast cancer and is among the more
commonly used protocols for preoperative management of
patients with locally advanced disease. However, despite itsAvailable online http://breast-cancer-research.com/content/10/4/R63
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general efficiency, as many as 50% of patients do not respond
adequately to this type of treatment. In the present study we
examined the expression of p27Kip1 and Skp2 before and after
preoperative doxorubicin-based chemotherapy and analyzed
their association with clinical and pathological parameters,
including prognosis and response to chemotherapy.
Materials and methods
Patients
Forty patients with locally advanced primary breast cancer
diagnosed and treated at Rambam Medical Center between
1999 and 2005 were included, once the approval of the insti-
tution's Human Investigation Committee had been obtained.
All patients initially received the same preoperative chemother-
apeutic regimen, which included cyclophosphamide 600 mg/
m2, doxorubicin (adriamycin) 60 mg/m2, and 5-fluorouracil
600 mg/m2, once every 3 weeks for up to six cycles. Some
patients received docetaxel (100 mg/m2, once every 3 weeks
for up to four cycles) at the discretion of the treating medical
oncologist. The median duration of treatment before surgery
was 5 months (range 3 to 8 months). Additional postoperative
treatment included radiotherapy and tamoxifen in estrogen
receptor (ER) and/or progesterone receptor (PgR) positive
patients. Response to chemotherapy was assessed in accord-
ance with standard criteria as follows: complete pathological
response was defined as the absence of malignant appearing
cells in the surgical specimen; partial response was defined as
at least 50% reduction in tumor size; and a reduction of less
than 50% in tumor size was classified as stable disease (poor
response). Therapy was to be terminated immediately if pro-
gressive disease became evident, and in such cases alterna-
tive chemotherapy or surgery was employed. Complete
clinical and pathological data were available for all patients.
Long-term follow-up data from the Medical Center's medical
charts and the Israel Cancer Registry were assessed.
Tissue specimen and immunohistochemistry
Paired tissue specimen obtained by core biopsy before initia-
tion of chemotherapy and from the surgical specimen after the
completion of chemotherapy were examined. Immunohisto-
chemical studies were performed on formalin-fixed, paraffin-
embedded tissue sections [36]. Sections (5 μm) were depar-
affinized with xylene and rehydrated in a series of ethanols. For
epitope retrieval, slides were heated in 1 mmol/l EDTA buffer
(pH 8), either in microwave oven at 92°C for 20 minutes for
p27Kip1, or in an Antigen Retrieval Processor (Milestone Inc.,
Sorsiole, Italy) at 120°C for 8 minutes for Skp2. After cooling,
slides were washed in distilled water. Skp2 staining was car-
ried out in the NexES IHC Immunostainer (Ventana Medical
Systems, Tucson, AZ, USA), in accordance with the manufac-
turer's instructions, using a monoclonal antibody (Zymed Inc.,
San Francisco, CA, USA) diluted at 1:100. This antibody can-
not distinguish between Skp2 and the F-box protein Skp2B.
Skp2B has little if any influence on the degradation of p27, but
in contrast to Skp2 (which is strictly localized in the nucleus),
Skp2B is localized only in the cytoplasm [37,38]. Because of
the restriction of our analysis to expression of nuclear Skp2,
the results reflect only levels of Skp2, and not those of Skp2B
(Figure 1).
Slides for p27Kip1 staining were treated for 10 minutes with
3% H2O2 in methanol in order to block endogenous peroxi-
dase, and for 30 minutes with 10% nonimmune rabbit serum
to block non specific protein binding. The slides were then
washed in water and soaked in washing buffer (pH 7.4; Opti-
max, Biogenex, San Ramon, CA, USA) for 5 minutes. For
p27Kip1 staining, slides were incubated overnight at 4°C with
the monoclonal p27Kip1 antibody diluted at 1:500. Staining
was completed with Histostain-plus kit (Zymed Inc.), in
accordance with the manufacturer's instructions. Color reac-
tion product was developed with amino ethyl carbazole. All
sections were counterstained with hematoxylin. For negative
controls, slide sections that were positive for staining were
treated with 10% nonimmune rabbit serum (Zymed Inc.)
instead of the primary antibody. No staining was observed in
any of these controls.
Scoring of immunohistochemical slides was done according
to the percentage of tumor cells exhibiting nuclear staining.
The range of Skp2 expression was between 0% and 40% of
cells, and that of p27 was between 0% and 80%, similar to
values reported in previous studies [16-18,26,36]. To define
high and low protein expression, we used a cut-off of 50% for
p27Kip1 and 10% for Skp2, which is the cut-off used in the
above-mentioned studies because it correlated well with
quantitative immunoblot data. These values were determined
following analysis of continuous variables (increments of 10%)
that showed that within the group of high expression no signif-
icant changes were found. When stained, cells exhibited sim-
ilar intensity of nuclear staining of Skp2 regardless of the
percentage of cells stained, and therefore the intensity of
staining was not included in the score. The specificity of immu-
nohistochemistry staining procedures for p27Kip1 and Skp2
was previously verified by comparing the protein levels, as
determined by immunohistochemistry, with the protein levels
determined by immunoblot analysis from the same tumor spec-
imens [23]. The examining pathologist was blinded to the
patients' clinical outcome and response rate of response to
chemotherapy
Statistical analysis
Statistical data analyses were performed using SPSS 11.0
statistical software package (SPSS Inc., Chicago, IL, USA).
First, the relationship between p27Kip1 and Skp2 and between
protein levels and different clinical and pathological features
and response to chemotherapy were explored using cross tab-
ulation and Pearson's χ2. Survival curves were constructed
using the Kaplan-Meier method and multivariate analysis by
Cox regression; P values less than 0.05 were considered sta-
tistically significant.Breast Cancer Research    Vol 10 No 4    Davidovich et al.
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Results
Skp2 expression before preoperative chemotherapy is 
inversely related to p27Kip1 levels, tumor differentiation, 
ER/PgR expression, and prognosis in locally advanced 
breast cancer
Initially, we examined the expression of Skp2 and p27Kip1 in 40
tumor samples obtained from patients with locally advanced
breast cancer before the initiation of preoperative chemother-
apy. The clinical and pathological characteristics of these
patients are summarized in Table 1. Skp2 levels were high in
17 patients (42%) and p27Kip1 levels were high in 32 patients
(80%). Skp2 levels were inversely related to p27Kip1 levels in
70% of tumors (29 patients; P = 0.011). When Skp2 levels
were low, p27Kip1 levels were high in 95.7% of patients, but in
those tumors in which Skp2 levels were high p27Kip1 levels
were low in only 41% of patients. Ten patients had high Skp2/
high p27Kip1 levels and one patient had low Skp2/low p27Kip1
levels. A typical representative immunohistochemical sample
is shown in Figure 1.
To examine the relationship between the expression of these
proteins and common parameters associated with tumor
behavior, we compared Skp2 and p27Kip1 levels with the clin-
icopathological features described in Table 1. A significant
inverse correlation was found between Skp2 expression and
tumor differentiation (P = 0.001), ER expression (P = 0.006),
and PgR expression (P = 0.005; Table 2). Thus, high expres-
sion of Skp2 was associated with loss of tumor differentiation
and negative ER or PR expression. We did not observe a sig-
nificant correlation between Skp2 levels and patient age (P =
0.083), lymph node status (P  = 0.083), tumor size (P  =
0.063), disease stage (P = 0.449), or Her2/neu expression (P
= 0.088; Table 2). Examination of the relation between p27Kip1
and patients' clinicopathological characteristics revealed a
strong positive association between the expression of p27Kip1,
and ER expression (P  = 0.001) and PR expression (P  =
0.017), and an inverse association with Her2/neu expression
(P = 0.022), but not with the other clinicopathological param-
eters (Table 2).
With a mean follow up of 42 months (18 to 82 months), dis-
ease recurrence was observed in 12 patients (30%). The
mean ± standard deviation time to recurrence was 21 ± 4.6
months, and overall seven patients died from their disease. We
found that the expression of Skp2 and p27Kip1 (pre-chemo-
therapy) was highly predictive for disease-free and overall sur-
vival (Figure 2). Thus, patients with high Skp2 expression had
significantly poorer disease-free and overall survival than did
patients expressing low Skp2 levels (P  = 0.001 and P  =
0.002, respectively). Similarly, patients exhibiting low p27Kip1
levels had significantly poorer survival rates than did patients
expressing high p27Kip1 levels (P = 0.003 and P = 0.009,
respectively). Among the clinical parameters, young age, neg-
ative ER expression, and lack of response to cyclophospha-
Figure 1
Representative immunohistochemistry slides for Skp2 and p27Kip1 staining in locally advanced breast cancer Representative immunohistochemistry slides for Skp2 and p27Kip1 staining in locally advanced breast cancer. Tumor cells of pretreated grade II inva-
sive duct cancer (T3N1MO) exhibiting strong and diffuse nuclear staining for Skp2 and low staining of p27Kip1 (upper row and insert). Note the 
inversely low Skp2 staining followed by high p27Kip1 staining in normal breast tissue (lower row). KIP, kinase inhibitor protein; Skp2, S-phase kinase 
protein 2.Available online http://breast-cancer-research.com/content/10/4/R63
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mide/doxorubicin (adriamycin)/5-fluorouracil (CAF) were
significantly associated with shorter disease-free survival. Mul-
tivariate analysis of all pretreatment variables, including Skp2
expression, p27Kip1 expression, age, tumor size, tumor grade,
nodal status, and ER, PR and Her2/neu receptor expressions,
showed that Skp2 expression (P = 0.002; odds ratio = 8.91)
and young age (P = 0.034) were the strongest predictors for
poor disease-free survival.
To examine whether chemotherapy affected the expression of
Skp2 and p27Kip1, we analyzed the expression of these pro-
teins after the completion of chemotherapy. Analysis was per-
formed on 35 tissue specimen (five patients had complete
pathological response). Overall, there were no significant
changes in the expression of either Skp2 or p27Kip1 after
chemotherapy (P = 0.190 and P = 0.104, respectively). How-
ever, in patients presenting with high Skp2, the expression of
Skp2 was downregulated after chemotherapy in 60% of
tumors (9/15), but expression was not upregulated in any of
the tumors with initially low levels of Skp2 (P = 0.001). Sur-
prisingly, despite the decrease in Skp2 levels after chemother-
apy, p27Kip1 levels were not increased in any of these tumors.
Moreover, p27Kip1 expression was in fact downregulated by
chemotherapy in 24% of tumors (7/29 patients), and in four
patients both Skp2 and p27Kip1 levels were downregulated.
Skp2 over-expression is associated with resistance to 
CAF but not to docetaxel
We next examined the association between pretreatment
expression levels of Skp2 and p27Kip1 and resistance to chem-
otherapy. All patients in this study were initially treated with
doxorubicin-based chemotherapy (CAF). A decrease of at
least 50% in tumor size was defined as a partial response,
whereas a reduction of less than 50% in tumor size was clas-
sified as stable disease or poor response. The associations of
expression levels of Skp2 and p27Kip1, and patients' clinical
and pathological characteristics with response to CAF are
outlined in Table 3. Twenty patients (50%) exhibited poor or
no response to CAF. Skp2 was over-expressed in 16 (80%) of
these patients. Only one case was detected in which Skp2
over-expression was associated with partial response to CAF.
Thus, high Skp2 levels were associated with poor response to
chemotherapy in 94.1% of cases in this study (P < 0.0001).
On the other hand, low Skp2 accurately predicted response to
CAF in 79.2% of cases (19/24 patients). p27Kip1 expression
was also found to be a predictor for response, but to a lesser
extent than Skp2 (P = 0.037). p27Kip1 expression was high in
19 (95%) of the tumors responding to CAF. However, p27Kip1
expression was also high in 14 (70%) of the poor responders.
Thus, high levels of p27Kip1 accurately predicted response to
CAF in only 57.6% of cases in this study. In contrast, low
expression of p27Kip1 was associated with response to CAF in
one patient only, thus correlating with poor response to CAF
in 85.7% of cases. We also examined the correlation between
the patients' clinical and pathological characteristics and
response to CAF. Poor tumor grade (P = 0.012) and clinically
negative lymph nodes (P = 0.022) were the only parameters
found to be associated with poor response to CAF (Table 3).
Multivariate analysis revealed that Skp2 was the strongest pre-
dictor for response to CAF (P > 0.001; ods ratio = 13.73).
Nineteen patients (47.5%) also received docetaxel after CAF
treatment. In 89.4% of these patients the reason for adding or
switching to docetaxel was poor response to CAF. Partial or
complete (2 patients) response was observed in 10 of these
patients (47.3%). Twelve patients (63.1%) had high Skp2 lev-
Table 1
Clinical and pathological characteristics of patients
Characteristic Value
Age (years; median [range]) 47 (29 to 79)
Histology (n [%])
Ductal 33 (82%)
Lobular 7 (18%)
Tumour grade (n [%])
G1 3 (7%)
G2 21 (53%)
G3 16 (40%)
Primary tumor (n [%])
T2 7 (17%)
T3 20 (50%)
T4 13 (33%)
Lymph node status (n [%])
Positive 24 (60%)
Negative 16 (40%)
Primary tumor (n [%])
IIA 4 (10%)
IIB 8 (20%)
IIIA 15 (33%)
IIIB 18 (38%)
Estrogen receptor status (n [%])
Positive 24 (60%)
Negative 16 (40%
Progesterone receptor status (n [%])
Positive 22 (55%)
Negative 18 (45%)
Her2 receptor status (n [%])
Positive 9 (23%)
Negative 31 (77%)Breast Cancer Research    Vol 10 No 4    Davidovich et al.
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els and 14 patients (73.6%) had high p27Kip1 levels. We did
not find a correlation between the expression of either Skp2 or
p27Kip1 and the rate of response to docetaxel (P = 0.764 and
P = 0.701, respectively). Of clinical importance, however, is
the observation that 50% of the high-Skp2 tumors that did not
respond to CAF exhibited a good response to docetaxel, sug-
gesting that docetaxel may be a better initial choice than CAF
in this subset of patients.
Complete tumor pathological response was identified in five
patients. A correlation between the expression of the proteins
and this type of response could not be established, mainly
because of the small number of patients in this subgroup. Sim-
ilarly, there was no correlation between complete elimination
of nodal metastases by chemotherapy (four patients) and
Skp2 or p27Kip1 expression (P  = 0.674 and P  = 0.711,
respectively).
Table 2
Expression of Skp2 and p27Kip1 in relation to the clinical and pathological characteristics of patients
Characeristic Skp-2 p27kip1
High Low P value High Low P value
Age (years)
>50 8 17 0.083 20 5 0.591
<50 9 16 13 2
Tumor grade
G1 3 0 0.001 3 0 0.162
G2 4 19 20 2
G3 13 3 11 5
Primary tumor
T2 1 6 0.063 7 0 0.105
T3 12 8 14 6
T4 4 9 12 1
Lymph node status
Positive 8 17 0.083 21 4 0.747
Negative 9 6 12 3
Stage
IIA 1 3 0.449 4 0 0.407
IIB 5 3 6 2
IIIA 7 8 11 4
IIIB 4 9 12 1
Estrogen receptor status
Positive 6 18 0.006 24 0 0.001
Negative 11 5 9 7
Progesterone receptor status
Positive 5 17 0.005 21 1 0.017
Negative 12 6 12 6
Her2 receptor status
Positive 6 3 0.088 3 5 0.002
Negative 11 20 30 2
P values relate to the differences between protein expression and the variables. P value < 0.05 was considered statistically significant. T, tumor 
size (according to the American Joint Committee on Cancer TNM staging system). KIP, kinase inhibitor protein; Skp2, S-phase kinase protein 2.Available online http://breast-cancer-research.com/content/10/4/R63
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Discussion
The use of preoperative chemotherapy has become the stand-
ard of care in patients with locally advanced breast cancer.
However, the correlation between commonly used clinical and
pathological features and respond to various chemotherapy
regimens is poor. Adriamycin-based chemotherapy is com-
monly used as the first-line treatment in this clinical setting.
However, adriamycin has considerable toxic effects and, in
particular, cardiac toxicity. This clinical side effect may be
exacerbated in patients with positive Her2/neu receptor status
by co-treatment with trastuzumab. Thus, the search for spe-
cific molecular markers that may serve as predictors for
response is of considerable clinical importance.
The expression of various cell cycle regulators was found to be
accurate in predicting tumor biology and clinical outcome.
Some of these proteins, including p27Kip1, were also found to
affect response to chemotherapy in different cancers and can-
cer cell lines. However, the data available on the impact of
p27Kip1 and other cell cycle proteins as predictors to response
to preoperative chemotherapy in patients with locally
advanced breast cancer are limited. In a recent report, Pohl
and coworkers [40] examined the expression of various cell
cycle regulatory proteins, including p27Kip1, in locally
advanced breast cancer and their association with complete
pathological response to preoperative chemotherapy. Twenty
nine patients were treated with CAF and 36 patients with epi-
Figure 2
Pretreatment Skp2 and p27Kip1 expression levels and survival Pretreatment Skp2 and p27Kip1 expression levels and survival. Shown are the associations between pretreatment Skp2 or p27Kip1 expression and (a) 
disease-free survival and (b) overall survival rates. Analyses were constructed using the Kaplan-Meier method. KIP, kinase inhibitor protein; Skp2, S-
phase kinase protein 2.Breast Cancer Research    Vol 10 No 4    Davidovich et al.
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rubicin/docetaxel. High expression of Ki-67 was associated
with complete pathological response, but there was no corre-
lation of expressions of p53, p21WAF1, p27Kip1, and cyclin D
with complete response to chemotherapy. However, that
study did not address the issue of whether any of these pro-
teins was associated with partial response, defined as a
reduction of at least 50% in tumor size. Because one of the
main aims of using preoperative chemotherapy is to achieve
significant reduction in tumor size in order to allow good local
control and possibly even permit breast-conserving surgery,
this issue has important clinical implications. Moreover, in as
many as 60% of complete clinical response, residual tumor is
found on pathological analysis. Thus, at present all patients
receiving preoperative chemotherapy must also undergo sur-
gery, so a marker that can predict good response rather than
complete pathological response may be of great clinical
importance. Ideally, such a marker should be reliably repro-
duced, rapidly performed and at minimal cost, such as immu-
nohistochemical studies. Studies have shown that gene
expression profiling studies may be used as predictors of
response to chemotherapy, but these studies are time con-
suming and expensive [41,42].
The role of Skp2 as an oncogene responsible for downregula-
tion of p27Kip protein levels is well established in a wide variety
of cancers, including early breast cancer. Studies have repeat-
edly shown that Skp2 enhances tumor progression and is
independently associated with poor prognosis, suggesting
that it may be a novel potential target for intervention. In the
present study we examined the expression of p27Kip1 and
Skp2 in patients with locally advanced breast cancers, before
and after chemotherapy, in order to determine their potential
roles as prognostic factors and as predictors of response to
preoperative chemotherapy. Our findings suggest that these
proteins, and in particular Skp2, may have important benefits
in this regard.
First, similar to previous reports in early breast cancer, in
locally advanced disease we found that high expression of
Skp2 or low expression of p27Kip1 correlated strongly with
pathological features associated with aggressive tumors,
including poor tumor differentiation and lack of receptors to
estrogen and progesterone. In addition, we found both Skp2
and p27Kip1 to be accurate predictors of disease-free and
overall survival, which suggests that these proteins may also
be useful markers in locally advanced cancer. Patients with
locally advanced disease already present with clinical features
that are strongly associated with poor prognosis, such as large
tumor size, positive lymph nodes and advanced stage. There-
fore, these features may not provide additional prognostic
information within this group of patients, as compared with
molecular markers such as Skp2, which may provide addi-
tional and important information in this subset of patients.
Interestingly, the percentage of patients presenting with high
Skp2 levels in locally advance disease was similar to that of
Table 3
The association of response to preoperative CAF treatment 
and patients' clinical and pathological characteristics with 
expression levels of Skp2 and p27Kip1
Characteristics Response P value
+-
Age (years)
>50 8 17 0.13
<50 9 6 0
Tumor grade
G1 + G2 16 8
G3 4 12 0.010*
Primary tumor
T2 5 2 0.151
T3 7 13
T4 8 5
Lymph node status
Positive 16 9 0.022*
Negative 4 11
Stage
IIA 3 1 0.289
IIB 2 6
IIIA 7 8
IIIB 8 5
Estrogen receptor status
Positive 15 9 0.053
Negative 5 11
Progesterone receptor status
Positive 14 8 0.057
Negative 6 12
HER-2 receptor status
Positive 6 3 0.212
Negative 14 17
p27Kip1
High 19 16 0.037*
Low 1 4
Skp2
High 1 16 0.0001*
Low 19 4
*P value < 0.05 was considered statistically significant. +, ≥ 50% 
reduction in tumor size; -, no response or <50% reduction in tumor 
size; KIP, kinase inhibitor protein; Skp2, S-phase kinase protein 2.Available online http://breast-cancer-research.com/content/10/4/R63
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patients presenting with high Skp2 levels in early breast can-
cer (40% and 42%, respectively) [36]. This suggests that high
expression of Skp2 in a given tumor is an inherent feature of
the tumor's biology rather than one that is acquired during pro-
gression of the disease. Second, we found that doxorubicin-
based chemotherapy did not significantly alter Skp2 or p27Kip1
levels, but when Skp2 levels did decrease no apparent
changes were observed in p27Kip1 levels. The mechanism
underlying these observations is unclear at present. However,
we previously examined the effect of doxorubicin on Skp2
expression in various breast cancer cell lines. We found that
although Skp2 levels decreased in some cell lines, in others
they did not, and these changes were dependent on the spe-
cific cell-type effect of doxorubicin on cell cycle arrest [43].
Moreover, in these experiments changes in Skp2 levels also
did not translate into changes in p27Kip1 levels. It is notewor-
thy, however, that despite the lack of changes in p27Kip1, Skp2
levels were independently associated with a significantly bet-
ter disease-free survival. This supports the concept that Skp2
has other important oncogenic effects and that reduction in
Skp2 levels is a rational therapeutic objective.
Finally, we found that Skp2 is an accurate predictor of
response to doxorubicin-based chemotherapy. Skp2 levels
were high in 80% of the poor responders; more specifically,
when Skp2 levels were high, 94% of the patients did not
respond sufficiently to doxorubicin-based therapy. Multivariate
analysis, including all available clinical and pathological param-
eters, revealed that Skp2 is an extremely accurate predictor for
response to doxorubicin-based (P  > 0.001; odds ratio =
13.73). Although the statistical significance for the ability of
Skp2 to predict response to CAF is high, the number of
patients in this study is rather small. Therefore, confirmatory
evidence from larger studies is required before we may pro-
pose that this marker be used to decide whether to administer
doxorubicin-based preoperative chemotherapy to patients
with breast cancer. It is also important to bear in mind that two
additional drugs are included in this regimen, which might
have influenced the findings of the present study to some
degree. In contrast, the relationship between Skp2 expression
and docetaxel resistance is difficult to interpret. The patients
who received docetaxel were a selected and relatively small
group of patients who did not respond to anthracycline-based
chemotherapy. Although in this group of patients the expres-
sion of Skp2 was not associated with docetaxel resistance,
larger studies conducted in patients receiving taxane-based
regimens are needed to determine the role of Skp2 as a pre-
dictor in taxane-based chemotherapy.
Conclusion
The results of the present study suggest that Skp2 may be an
accurate biological marker for prognosis as well as a predictor
of response to doxorubicin-based chemotherapy in locally
advanced breast cancer. Furthermore, these results support
previous studies that emphasize the oncogenic properties of
Skp2; hence, this protein may be a novel target for future
interventions.
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